---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-032011"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:53:51.488865+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints former ChemoCentryx CMO Rita Jain to board

## Summary
- Dr. Rita Jain appointed to Avalo's Board of Directors effective June 17, 2025.
- She previously served as EVP and CMO at ChemoCentryx, advancing Tavneos for ANCA vasculitis.
- Received initial non-qualified stock option for 40,200 shares, vesting over three years.
- Board also adopted Amended Non-Employee Director Compensation Plan to attract qualified directors.

## SEC filing metadata
- accession: 0001628280-25-032011
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/0001628280-25-032011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/avtx-20250617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-032011
- JSON: https://secwatch.observer/filing/0001628280-25-032011.json
- Plain text: https://secwatch.observer/filing/0001628280-25-032011.txt

## Key facts
- Executive change
  Rita Jain was appointed as Director at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/0001628280-25-032011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.